X4 PHARMACEUTICALS, INC Long-Term Debt, Maturity, Year Five
X4 PHARMACEUTICALS, INC (XFOR) had Long-Term Debt, Maturity, Year Five of $8.10 million as of 2019-09-30, per its 10-Q filed 2019-11-07.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2019-11-07
- 2019-09-30: Long-Term Debt, Maturity, Year Five $8.10M.
- 2019-06-30: Long-Term Debt, Maturity, Year Five $8.10M.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2019-09-30 | $8.10M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $8.10M 10-Q · filed 2019-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |